Supplementary Material

Supplementary methods

Western blot analysis

Cediranib-treated and control tumours were homogenized in non-denaturing lysis buffer (Cell Signaling Technology) containing 1x protease and phosphatase inhibitor cocktail (Roche). Protein concentrations were determined by BioRad™ protein assay (Biorad) and 30 µg of protein was separated by SDS PAGE using NuPAGE Novex 4-12% Bis-Tris precast gels and electrophoretically transferred to nitrocellulose membrane (0.2µm). Membranes were blocked using 3% ECL advance blocking reagent and probed with primary antibody in blocking buffer overnight at 4°C. Proteins were detected using HRP-conjugated secondary antibody (DAKO) and visualized with enhanced chemiluminescence reagents (GE Healthcare). Phospho-VEGFR2 and total-VEGFR2 antibodies were obtained from Cell Signaling Technology and β-actin antibody was obtained from Abcam.

Supplementary figure 1. Phosphorylation and expression levels of VEGFR2 in tumors of TH-*MYCN* mice after 2 and 7 days of daily treatment with 6mg/kg cediranib, determined using western blot analysis and compared to control tumors. β-actin was used as a loading control.